MedTrace Logo

Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye

NCT04521465 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2021-04-15

No results posted yet for this study

Summary

This PMCF study is carried out following successful CE marking of NovaTears® + Omega-3 and is intended to generate systematic clinical data on the safety and performance of the device when used in accordance with the intended purpose.

Conditions

  • Evaporative Dry Eye Disease

Interventions

DEVICE

NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)

Eye drops

Sponsors & Collaborators

  • Novaliq GmbH

    lead INDUSTRY

Principal Investigators

  • Sonja Kroesser, PhD · Novaliq GmbH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-09
Primary Completion
2021-02-17
Completion
2021-02-17

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04521465 on ClinicalTrials.gov